xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 2021, 3, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22741 by Stanford University, Wiley Online Library on [01/07/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

498

International consensus statement on rhinosinusitis

At 90 days, significant improvement in ethmoid sinus obstruction, nasal obstruction/congestion score, sense of smell, and reduced need for RESS in the implant group vs controls. One patient with epistaxis.

At 90 days, significant reduction in bilateral polyp grade, ethmoid sinus obstruction in implant

group vs controls. Significant improvement in nasal obstruction/congestion score in patients with greater polyp burden in implant group vs controls. At 90 days, 53% of treated patients

were no longer indicated for RESS compared to 23% of controls. No increase in IOP or cataracts

TABLE X-20 Evidence for CRSwNP management with steroid eluting implants Study Year LOE Study Design Study Groups Clinical Endpoint Conclusions Stolovitzky 1608 2019 1 Meta-analysis (n = 375) 2 RCTS of CRSwNP patients who were deemed candidates forRESS Nasal obstruction and congestion (NOSE) score Endoscopically assessed polyp grade and ethmoid obstruction Need for RESS At 90 days, patients receiving implants and nasal steroid spray had significant improvements in nasal obstruction/congestion score, bilateral polyp grade, and ethmoid sinus obstruction Kern 1607 2018 2 Multicenter randomized controlled, single-blinded trial (n = 300) CRSwNP patients who were deemed candidates for RESS Forwith 1606

compared to control patients using steroid spray alone. 59% of treated patients were no longer

indicated for RESS compared to 31% of controls. Four patients had nasal discomfort and 1 patient had epistaxis.

At 6 months, significant improvement in NOSE score, reduction in ethmoid sinus obstruction and bilateral polyp grade in implant group vs controls. Panel review found polyp grade improvement reached significance only in

patients with severe polyps. At 6 months, 31% of treated patients were no longer indicated for

RESS compared to 11% of controls. No increase in IOP or cataracts

Nasal obstruction, congestion score and NOSE score

Endoscopically assessed bilateral polyp grade and ethmoid obstruction by review panel Need for RESS

Nasal obstruction, congestion score and NOSE score

Endoscopically assessed bilateral polyp grade and ethmoid obstruction by clinicians Need for RESS

Nasal obstruction, congestion score and NOSE score

Endoscopically assessed bilateral polyp grade and ethmoid obstruction assessed by clinician and review panel Need for RESS

who were deemed candidates for RESS

who were deemed candidates for RESS

CRSwNP patients

CRSwNP patients

single-blinded trial (n = 100)

single-blinded (n = 100)

randomized

controlled,

randomized

controlled,

Han 1605 2014 2 Multicenter

2016 2 Multicenter

results of Han 1605 2014)

(6month